Skip to main content
SAM CHUN DANG PHARM CO. LTD logo

SAM CHUN DANG PHARM CO. LTD — Investor Relations & Filings

Ticker · 000250 ISIN · KR7000250001 KO Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2022-02-28 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 000250

About SAM CHUN DANG PHARM CO. LTD

http://www.scd.co.kr/english/scd/index.…

SAM CHUN DANG PHARM CO. LTD. is a pharmaceutical company focused on the development, manufacturing, and sale of medications. The company specializes in ophthalmic products, establishing itself as a significant player in the generic eye care market. Its portfolio also extends to other therapeutic areas, including antibiotics and medications for the circulatory system. The company produces a range of ethical (prescription) and over-the-counter (OTC) drugs in both sterile and non-sterile forms. Manufacturing operations adhere to international quality standards, holding both US and EU Good Manufacturing Practice (GMP) certifications.

Recent filings

Filing Released Lang Actions
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from Samchundang Pharm regarding the adjustment of the conversion price of convertible bonds due to a decline in market price. This type of disclosure, which details changes to capital structure instruments (convertible bonds), falls under the 'Capital/Financing Update' category as it directly relates to financing activities and the terms of issued debt securities.
2022-02-28 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Samchundang Pharm. It outlines the date, location, and agenda items (approval of financial statements, election of directors and auditors, and remuneration limits). This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon. It fits the definition of Proxy Solicitation & Information Statement (PSI).
2022-02-24 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and details of an Investor Relations (IR) event (Non-deal Roadshow). It provides the date, location, purpose, and contact information for the meeting. Since it is an announcement of an upcoming event and the availability of materials rather than the presentation slides themselves, it falls under the category of a regulatory filing announcement or general regulatory notice.
2022-02-14 Korean
[기재정정]기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a regulatory filing from Samchundang Pharm announcing the scheduling and details of an Investor Relations (IR) event (Non-deal Roadshow). It includes specific dates, locations, and the purpose of the meeting. While it mentions IR materials, the document itself is the official notice/announcement of the event to the regulatory body (KIND), fitting the definition of a general regulatory filing or announcement regarding corporate events.
2022-02-14 Korean
풍문또는보도에대한해명(미확정)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system titled 'Clarification of Rumors or Reports (Undetermined)'. It addresses specific media reports regarding investment and business negotiations. Since it is a regulatory disclosure regarding corporate developments that does not fit into specific categories like M&A or financial reports, it is classified as a general Regulatory Filing (RNS).
2022-02-03 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Samchundang Pharm) announcing a significant change in financial structure (revenue/profit fluctuation of over 30%). This is a standard regulatory disclosure requirement in the Korean market (DART system) for listed companies to report preliminary financial results before the final audit is completed. Since it provides key financial highlights and reasons for the change, it fits the definition of an Earnings Release (ER). FY 2021
2022-01-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.